Depression Screening Market is Expected to Grow at a CAGR of 4.5% from 2016 to 2023

Depression screening/mental health market by disorder (anxiety, mood disorders, depression, bipolar, psychotic), by diagnosis, by treatment, by end user- Global Forecast till 2023

Pune, India - August 30, 2017 /MarketersMedia/ —

Market Highlights
The global depression screening/mental health market has been evaluated as a moderately growing market and it is expected to continue growing in the near future. Increasing cases of patients with various mental disorders, rising investments in R&D, changing and stressful lifestyle are driving the growth for the market.
The market for depression screening/mental health was around USD 8263.6 million in 2016 and is expected to reach USD 11245.6 million which is projected to grow at a CAGR of 4.5% by 2023.

Considering the global scenario of the Depression Screening/Mental Health market, the Americas is known to be the largest market. Many top global pharmaceutical companies have their base in this region leading the innovation and new solution development. These companies like Eli Lilly and Company, Pfizer Inc. and some other are spending a rather large amount on R&D for market growth. According to Canadian Mental Health Association, 1% Canadian population is suffering from Schizophrenia while 5% of Canadian household population is suffering from anxiety disorders.

Key players for global depression screening/mental health market:
• Alkermes (Republic of Ireland),
• ALLERGAN (Republic of Ireland),
• AstraZeneca (UK),
• Bristol-Myers Squibb Company (US),
• Eli Lilly and Company (US),
• F. Hoffmann-La Roche Ltd (Switzerland),
• Johnson & Johnson Services, Inc. (US),
• Novartis AG (Switzerland),
• Otsuka Holdings Co.,Ltd. (Japan),
• Pfizer Inc. (US),
• others.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/3806

Major players of this industry are funding R&D to derive effective solutions for mental health. Major players of this market are holding majority of market share while due to high investment cost, medium and small companies mainly focusing only on manufacturing of drugs rather than R&D.

In 2015, U S Food and Drug Administration (FDA) approved three major drugs which can be useful for the treatment of schizophrenia and other mental disorders. These drugs are Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable, Otsuka Holdings Co.,Ltd.’s Rexulti (brexpiprazole), and ALLERGAN’s Vraylar (cariprazine).

Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Depression Screening/Mental Health Market- Global Forecast till 2023”

Considering the global scenario of the Depression Screening/Mental Health market, the Americas is known to be the largest market. Many top global pharmaceutical companies have their base in this region leading the innovation and new solution development. These companies like Eli Lilly and Company, Pfizer Inc. and some other are spending a rather large amount on R&D for market growth. According to Canadian Mental Health Association, 1% Canadian population is suffering from Schizophrenia while 5% of Canadian household population is suffering from anxiety disorders.

Access Report Detail @ https://www.marketresearchfuture.com/reports/depression-screening-mental-health-market-3806

Table of Content

1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
5. Market Factor Analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
5.6 Merger and Acquisition Landscape
5.7 Upcoming trends
5.7.1 Market trends
5.7.2 Technological trends
5.7.3 Insurance & Regulations
5.7.4 Others
6. Global depression screening/mental health market by diagnosis
Continue……………….

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact Info:
Name: Akash Anand
Organization: Market Research Future
Address: Magarpatta Road, Hadapsar,
Phone: 6468459349

Source URL: https://marketersmedia.com/depression-screening-market-is-expected-to-grow-at-a-cagr-of-4-5-from-2016-to-2023/232238

For more information, please visit https://www.marketresearchfuture.com

Source: MarketersMedia

Release ID: 232238